Beta Drugs Limited has entered into a definitive agreement to acquire a 66.09 per cent stake in Nivian Lifesciences Private Limited for ₹69.4 crore, valuing the company at ₹105 crore. The stake will be acquired from certain existing shareholders of Nivian.
Founded in 2019, Nivian Lifesciences is a fast-growing branded formulations company focused on In-Vitro Fertilisation (IVF) therapy in India. The IVF segment has witnessed strong growth, recording a compound annual growth rate (CAGR) of around 20 per cent over the past five years, and continues to attract significant interest across both IVF services and pharmaceutical products. The total market size for IVF therapy in India is estimated at ₹1,500–1,700 crore.
Nivian was established by Nilesh Auti, who has over a decade of experience in the IVF space, including stints at leading companies such as Bharat Serums and Vaccines. Under his leadership, the company has built a strong portfolio of niche IVF products and has rapidly emerged as one of the fastest-growing players in the segment. For the nine months ended December 2025,
Nivian reported net sales of ₹30.30 crore and is expected to close FY26 with revenues of approximately ₹43 crore.
The acquisition is expected to provide a strategic growth platform for Beta Drugs, enabling it to strengthen its presence in the women’s health and fertility drug market in India. The combination of Beta’s manufacturing capabilities and Nivian’s product development, marketing and sales strengths is expected to enhance Beta’s position in the branded formulations market, particularly in complex formulations across oncology, cosmetology and IVF.
As part of the transaction, founder Nilesh Auti will continue to lead Nivian’s marketing and operations and will remain invested in the company as it scales its business. The integration is expected to accelerate Nivian’s growth while reinforcing its leadership position in the IVF pharmaceutical segment in India.